Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Pharmaceutical intermediates Atazanavir Raw Materials Powder
Product Overview:
Azanavir is a new type of HIV-1 protease inhibitor developed by Bristol-Myers Squibb. Azanavir sulfate was released in the United States on June 20, 2003 and in Europe on March 2, 2004 under the trade name Reyataz.
Pharmaceutical intermediates Atazanavir Raw Materials Powder Attributes
CAS:198904-31-3
MF:C38H52N6O7
MW:704.86
EINECS:812-543-8
Specification: 99% min Atazanavir Powder
Sample:Atazanavir
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Pharmaceutical intermediates Atazanavir Raw Materials Powder Details
Atazanavir Powder Usage and Synthesis.
Azanavir is an inhibitor of azeptide HIV-1 protease. The product selectively inhibits the specific processing of viral Gag and GAG-pol polymers in HIV-1-infected cells, thereby blocking the formation of mature viruses. In vitro antiviral activity: The mean 50% inhibitory concentration (IC50) of azanavir against a large number of laboratory and clinical isolates of HIV-1 virus isolated from peripheral blood mononuclear cells, macrophages, CIM-SS cells, and MT2 cells without human serum was 2-5 nm.
Pharmacological action of Atazanavir.
This product is a novel azopeptidase protease inhibitor (PI). Its activity in vitro is not the same as that of non-peptide PIs such as Nelfinavir. This product is designed according to the X-ray diffraction study of enzym-azopeptidase complex and has a C-2 symmetric chemical structure. It is a highly selective and efficient inhibitor of HIV-1 protease, which inhibits the production of viral structural proteins, reverse transcriptase, integrase and protease by blocking the cleavage of viral gap and GAP-POL precursor polymerase, so that HIV-1-infected cells release non-infectious immature viral particles. This product has stronger inhibitory activity against multiple strains of HIV-1 virus than other PIs, and the median effective concentration (EC50) in vitro medium is 2.6 ~ 5.3nmol/L, and the 90% effective concentration (EC90) is 9 ~ 15nmol/L.
In vitro study of Atazanavir.
Atazanavir has effective activity against wild-type viruses in vitro with EC50 and EC90 of 2-5nM and 9-15nM, respectively. Atazanavir can effectively induce endoplasmic reticulum stress response in glioma cells, and the levels of GRP78 and CHOP are increased, and caspase-4 is activated, leading to cell death.
Product method of Bulk Atazanavir Powder.